Human Respiratory Syncytial Virus Vaccine

Creative Biolabs is a world leader in the field of viral vaccine development. By consistently delivering the highest standards of quality, professionalism, and integrity, we want to become the partner of a choice for your requirements. With our extensive experience and advanced platform, we are therefore confident in offering the best vaccine development services for human respiratory syncytial virus. We guarantee the finest results for our customers all over the world.

Human respiratory syncytial virus (HRSV) is a single-stranded RNA enveloped virus from paramyxovirus family which it is related to human metapneumovirus. In HRSV, G and F proteins include the major glycoprotein spikes on the viral membrane and are major targets of neutralizing antibodies, M is the matrix protein and SH is a third integral membrane protein. The virus is a syncytial virus and is the major cause of acute lower respiratory tract infections worldwide in infants and children younger than 2 years, leading to severe viral bronchiolitis associated with the subsequent development of recurrent wheezing and requiring hospitalization and, rarely, causing death. HRSV is considered to be spread via droplets or direct contact of the conjunctiva, nasal mucosa, or fomites. Except for the adverse effects in airway tissues, HRSV infection can also cause neurologic manifestations in the host, such as seizures and encephalopathy.

Live HRSV Vaccines

A live attenuated HRSV vaccine for intranasal administration is established which can be introduced in combinations as desired to achieve gradations of attenuation, could induce both systemic and local immunity and therefore protect against upper respiratory disease. Furthermore, the immunization of this vaccine may closely resemble the response to natural infection. While the live intranasal vaccines could induce local mucosal as well as systemic immunity, hence the intranasal route partially escapes the immunosuppressive effects of maternal serum antibodies. Among several different strategies for vaccine development, the most promising candidate is developed by serial passage at increasingly suboptimal temperature followed by chemical mutagenesis.

Subunit HRSV Vaccines

F and G subunits of HRSV have been developed as potential candidate vaccines. The subunit HRSV vaccines containing a novel chimeric F/G glycoprotein or purified F protein were delivered intramuscularly and tested in a variety of rodent and primate models. The experimental data indicated the formulation of vaccine with the novel adjuvant QS-21 can augment neutralizing antibody and Th-1-type antibody responses. Results show that subunit HRSV vaccines are safe and moderately immunogenic in the populations either the elderly or children with chronic cardiac or pulmonary disease, therefore, suggest they might be the most useful vaccines to against HRSV.

Gene-based and Vectored HRSV Vaccines

We utilized the substantially greater growth and stability vectors to express the HRSV G and F protective antigens from added transcriptional units. The nucleic acid vaccines and replication-deficient vectors include human and chimpanzee adenovirus vectors or MVA-vectored vaccines containing one or more HRSV antigen inserts. The vaccines behave biologically more like live-virus vaccines in which antigens would be produced intracellularly, leading to induction of cytotoxic CD8⁺ T cells and a more Th1-biased cytokine response. The inserted genes were surprisingly stable and suitable for vaccine manufacture.

Nanoparticle HRSV Vaccines

Another type of HRSV vaccine is nanoparticle vaccine which has the considerable interest in the vaccine field. Biodegradable synthetic polymers can be used to create particles loaded with or chemically conjugated with antigens and adjuvants of choice. Nanoparticle vaccines that incorporate antigenic components from HRSV have been shown to stimulate mucosal and systemic immune responses in preclinical studies. Nanoparticle vaccines have a huge potential in HRSV vaccine development.

Creative Biolabs is a highly proactive, robust, and diversified company with a strong, scientifically-proven background of viral vaccine development. We have experts who are able to help you with the vaccine development against human respiratory syncytial virus. If you are interested in our services, please contact us for more details.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.